Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,364 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 4:33 PM EDT
Terminated No phase listed Observational

Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy

NCT02445235
View directory record Official record
Conditions
Chronic Pain, Fungal Infection
Interventions
Patient Reported Outcome Survey Tool
Other
Lead sponsor
Bracane Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Lexington, Kentucky • Sevierville, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 3 Interventional

Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study

NCT00177710
View directory record Official record
Conditions
Lung Transplantation, Fungal Infections
Interventions
Amphotericin B
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 22, 2026, 4:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pretomanid in Adults With Hepatic Impairment

NCT02422524
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure

NCT05799976
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
Interventions
Text message nudge
Behavioral
Lead sponsor
Mitesh Patel
Industry
Eligibility
18 Years and older
Enrollment
29,334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 22, 2026, 4:33 PM EDT
Withdrawn Not applicable Interventional

Vitamin D in Active Tuberculosis (TB) Study

NCT00788320
View directory record Official record
Conditions
Tuberculosis
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger

NCT00618449
View directory record Official record
Conditions
Trachoma, Chlamydia Trachomatis
Interventions
Azithromcyin, Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
1,139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 22, 2026, 4:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

NCT05182749
View directory record Official record
Conditions
Shigellosis
Interventions
bacteriophage, Placebo
Biological · Other
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT00646958
View directory record Official record
Conditions
Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions
Radezolid, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Bacteria Entering the Blood Stream From Tooth Extractions and Tooth Brushing

NCT00454285
View directory record Official record
Conditions
Bacteremia
Interventions
Effect of Amoxicillin on bacteremia following a single-tooth extraction
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

NCT04870138
View directory record Official record
Conditions
Gonococcal Infection
Interventions
Azithromycin, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7527
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

NCT05363449
View directory record Official record
Conditions
Tinea Cruris, Tinea Pedis
Interventions
UHE-103 Cream, Naftin (naftifine hydrochloride) Cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
San Diego, California • Thousand Oaks, California • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 4 Interventional

Topical Penlac Nail Lacquer for Onychomycosis in Children

NCT01419847
View directory record Official record
Conditions
Onychomycosis
Interventions
Ciclopirox, Placebo
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 22, 2026, 4:33 PM EDT
Completed No phase listed Observational

Hidradenitis Suppurativa Mail Survey

NCT03572738
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
67 participants
Timeline
2018 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 22, 2026, 4:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228
View directory record Official record
Conditions
Lyme Borreliosis, Nervous System
Interventions
VLA15 with Alum, VLA15 without Alum
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 39 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Mesa, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail

NCT02267356
View directory record Official record
Conditions
Onychomycosis
Interventions
VT-1161, Placebo
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 70 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Tucson, Arizona • Oceanside, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Tularemia Vaccine Comparison

NCT01150695
View directory record Official record
Conditions
Tularaemia
Interventions
Placebo, Undiluted Francisella tularensis live attenuated vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant

NCT01817075
View directory record Official record
Conditions
Bacterial Infection, Benign Neoplasm, Malignant Neoplasm, Methicillin-Resistant Staphylococcus Aureus Infection, Myeloid Neoplasm, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Interventions
Chlorhexidine Gluconate Skin Cleanser, Laboratory Biomarker Analysis, Mild Soap Skin Cleanser, Questionnaire Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Months to 21 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
53
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 4:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Individuals With Immune System Problems That Lead to Fungal Infections

NCT01386437
View directory record Official record
Conditions
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:33 PM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

NCT05393037
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, Placebo, PCV15, PPSV23, PCV15 - Part B
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 22, 2026, 4:33 PM EDT